VRCA — Verrica Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $60.64m
- $50.84m
- $35.58m
U.S. STOCKS ON THE MOVE-General Electric, BlackRock, Aadi Bioscience
U.S. STOCKS ON THE MOVE-Alteryx, Costco, Verrica Pharmaceuticals
Verrica Pharma up as skin disease drug study in Japan shows promise
Brief: Verrica Pharmaceuticals’ Partner Torii Pharmaceutical Announces Positive Top-Line Results From Confirmatory Phase 3 Trial Of TO-208
Brief: Verrica Pharmaceuticals Q3 adjusted EPS USD -0.32
Brief: Verrica Issues Statement In Support Of FDA’S Warning Letters To Manufacturers And Retailers For Producing And Selling Unapproved Products For The Treatment Of Molluscum Contagiosum
Verrica Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Brief: Verrica Pharmaceuticals Reports Second Quarter 2023 Financial Results
Brief: Verrica Pharmaceuticals Inc. Q2 Adjusted EPS USD -0.21
Verrica Pharmaceuticals Inc expected to post a loss of 21 cents a share - Earnings Preview
Brief: Verrica Pharmaceuticals Announces Acceptance Of Abstract Featuring Clinical Data Of VP-315
Verrica Pharma down on profit-taking after skin therapy approval
Brief: Verrica Pharmaceuticals Enters Into Non-Binding Term Sheet For Term Loan Facility Of Up To $125 Million
US FDA approves Verrica's skin disease treatment (updated)
US FDA approves Verrica's skin disease treatment
Brief: Verrica Pharmaceuticals Announces FDA Approval Of YCANTH Topical Solution As The First FDA Approved Treatment Of Pediatric And Adult Patients With Molluscum Contagiosum
Verrica Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Verrica Pharmaceuticals Reports Q1 2023 Financial Results
Verrica Pharmaceuticals Inc expected to post a loss of 19 cents a share - Earnings Preview